{Reference Type}: Journal Article
{Title}: Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers.
{Author}: Azzolina D;Consonni D;Ferrante D;Mirabelli D;Silvestri S;Luberto F;Angelini A;Cuccaro F;Nannavecchia AM;Oddone E;Vicentini M;Barone-Adesi F;Cena T;Mangone L;Roncaglia F;Sala O;Menegozzo S;Pirastu R;Tunesi S;Chellini E;Miligi L;Perticaroli P;Pettinari A;Bressan V;Merler E;Girardi P;Bisceglia L;Marinaccio A;Massari S;Magnani C; ;
{Journal}: Thorax
{Volume}: 78
{Issue}: 8
{Year}: Aug 2023 10
{Factor}: 9.102
{DOI}: 10.1136/thorax-2021-217862
{Abstract}: BACKGROUND: Exposure to asbestos increases the risk of lung cancer and mesothelioma. Few studies quantified the premature occurrence of these diseases in asbestos-exposed workers. Focus on premature disease onset (rate advancement or acceleration) can be useful in risk communication and for the evaluation of exposure impact. We estimated rate advancement for total mortality, lung cancer and pleural mesothelioma deaths, by classes of cumulative asbestos exposure in a pooled cohort of asbestos cement (AC) workers in Italy.
METHODS: The cohort study included 12 578 workers from 21 cohorts, with 6626 deaths in total, 858 deaths from lung cancer and 394 from pleural malignant neoplasm (MN). Rate advancement was estimated by fitting a competitive mortality Weibull model to the hazard of death over time since first exposure (TSFE).
RESULTS: Acceleration time (AT) was estimated at different TSFE values. The highest level of cumulative exposure compared with the lowest, for pleural MN AT was 16.9 (95% CI 14.9 to 19.2) and 33.8 (95% CI 29.8 to 38.4) years at TSFE of 20 and 40 years, respectively. For lung cancer, it was 13.3 (95% CI 12.0 to 14.7) and 26.6 (95% CI 23.9 to 29.4) years, respectively. As for total mortality, AT was 3.35 (95% CI 2.98 to 3.71) years at 20 years TSFE, and 6.70 (95% CI 5.95 to 7.41) at 40 years TSFE.
CONCLUSIONS: The current study observed marked rate advancement after asbestos exposure for lung cancer and pleural mesothelioma, as well as for total mortality.